2.50
Hdl Handle:
http://hdl.handle.net/10541/109032
Title:
Colony-stimulating factors in the clinic.
Authors:
Testa, Nydia G; Dexter, T Michael
Abstract:
Recombinant purified human haemopoietic growth factors are available for clinical trials and some have been licensed for therapeutic use. Some haemopoietic lineages (erythroid, neutrophilic, monocyte-macrophagic) can be selectively stimulated in order to ameliorate the cytopenias that follow cytotoxic treatment, or that characterize some haematological syndromes, and to stimulate mature cell function. Advances in the knowledge of receptor-ligand interactions and of transduction mechanisms, plus the production of synthetic or mutant molecules that may mimic, potentiate or antagonize the effects of the natural growth factors, should make novel therapeutic approaches possible.
Affiliation:
Cancer Research Campaign Department of Experimental Haematology, Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK.
Citation:
Colony-stimulating factors in the clinic. 1992, 3 (6):687-92 Curr. Opin. Biotechnol.
Journal:
Current Opinion in Biotechnology
Issue Date:
Dec-1992
URI:
http://hdl.handle.net/10541/109032
DOI:
10.1016/0958-1669(92)90017-D
PubMed ID:
1283087
Type:
Article
Language:
en
ISSN:
0958-1669
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorTesta, Nydia Gen
dc.contributor.authorDexter, T Michaelen
dc.date.accessioned2010-08-04T10:04:58Z-
dc.date.available2010-08-04T10:04:58Z-
dc.date.issued1992-12-
dc.identifier.citationColony-stimulating factors in the clinic. 1992, 3 (6):687-92 Curr. Opin. Biotechnol.en
dc.identifier.issn0958-1669-
dc.identifier.pmid1283087-
dc.identifier.doi10.1016/0958-1669(92)90017-D-
dc.identifier.urihttp://hdl.handle.net/10541/109032-
dc.description.abstractRecombinant purified human haemopoietic growth factors are available for clinical trials and some have been licensed for therapeutic use. Some haemopoietic lineages (erythroid, neutrophilic, monocyte-macrophagic) can be selectively stimulated in order to ameliorate the cytopenias that follow cytotoxic treatment, or that characterize some haematological syndromes, and to stimulate mature cell function. Advances in the knowledge of receptor-ligand interactions and of transduction mechanisms, plus the production of synthetic or mutant molecules that may mimic, potentiate or antagonize the effects of the natural growth factors, should make novel therapeutic approaches possible.en
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAnimals-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshColony-Stimulating Factors-
dc.subject.meshGranulocyte Colony-Stimulating Factor-
dc.subject.meshGranulocyte-Macrophage Colony-Stimulating Factor-
dc.subject.meshGrowth Substances-
dc.subject.meshHumans-
dc.subject.meshNeoplasms-
dc.subject.meshNeutropenia-
dc.subject.meshRecombinant Proteins-
dc.titleColony-stimulating factors in the clinic.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Department of Experimental Haematology, Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK.en
dc.identifier.journalCurrent Opinion in Biotechnologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.